Stemline Therapeutics, Inc.

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -1.47%131.020.0%$2314.17m
BNGOBioNano Genomics, Inc. 18.50%9.800.0%$2016.46m
GILDGilead Sciences, Inc. -0.06%66.941.0%$649.72m
AMGNAmgen, Inc. 0.58%253.501.3%$564.60m
CRSPCRISPR Therapeutics AG 1.83%188.490.6%$487.99m
REGNRegeneron Pharmaceuticals, Inc. 0.43%537.782.7%$478.09m
ALXNAlexion Pharmaceuticals, Inc. 1.19%159.732.0%$470.59m
NVAXNovavax, Inc. 3.74%126.9892.9%$417.43m
ILMNIllumina, Inc. 0.34%406.253.5%$396.72m
SRPTSarepta Therapeutics, Inc. 1.36%98.2413.8%$364.79m
VRTXVertex Pharmaceuticals, Inc. -0.44%237.591.9%$361.85m
BIIBBiogen, Inc. -0.25%269.441.7%$321.90m
BNTXBioNTech SE 2.86%108.440.0%$298.33m
EXASEXACT Sciences Corp. 1.30%150.0019.6%$243.95m
PACBPacific Biosciences of California, Inc. 3.06%37.427.4%$228.17m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called “StemScreen®” which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed therapeutics, diagnostics, and drug screening.